Anti-CD3 treatment also demonstrated efficacy in multiple randomized trials in patients with recent-onset type 1 diabetes, transiently preserving β cells’ insulin secretory capacity [7–9]. This evidence concerns the gene INS and type 1 diabetes mellitus.